Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Capital Expenditures (2016 - 2025)

Seres Therapeutics' Capital Expenditures history spans 11 years, with the latest figure at -$215000.0 for Q3 2025.

  • For Q3 2025, Capital Expenditures fell 1753.85% year-over-year to -$215000.0; the TTM value through Sep 2025 reached $367000.0, down 58.76%, while the annual FY2024 figure was $380000.0, 95.24% down from the prior year.
  • Capital Expenditures for Q3 2025 was -$215000.0 at Seres Therapeutics, down from $160000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $4.1 million in Q3 2021 and bottomed at -$215000.0 in Q3 2025.
  • The 5-year median for Capital Expenditures is $622000.0 (2022), against an average of $1.1 million.
  • The largest annual shift saw Capital Expenditures soared 5032.0% in 2023 before it crashed 1753.85% in 2025.
  • A 5-year view of Capital Expenditures shows it stood at $1.6 million in 2021, then decreased by 23.0% to $1.2 million in 2022, then dropped by 27.82% to $877000.0 in 2023, then plummeted by 58.15% to $367000.0 in 2024, then tumbled by 158.58% to -$215000.0 in 2025.
  • Per Business Quant, the three most recent readings for MCRB's Capital Expenditures are -$215000.0 (Q3 2025), $160000.0 (Q2 2025), and $55000.0 (Q1 2025).